Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.
Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.
Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...
Research has revealed that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...
The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...
Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC).
Casdozokitug is a monoclonal antibody commercialized by Coherus BioSciences, with a leading Phase II program in Hepatocellular Carcinoma.
Hepatitis delta virus testing in those with chronic hepatitis B is low, and improvements are needed to reduce long-term, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback